Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | SCD | O00767 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23555558 | 0.85 | TP53 (0.62) | TP53SCDLMNAHDAC6TRPA1 | |
| SCHEMBL23555555 | 0.84 | TP53 (0.58) | TP53SCDLMNAHDAC6TRPA1 | |
| SCHEMBL23555767 | 0.76 | ALDH1A1 (0.55) | LMNAHDAC6MEN1KMT2A | |
| SCHEMBL23555556 | 0.75 | TP53 (0.57) | TP53SCDLMNAHDAC6TRPA1 | |
| SCHEMBL7003110 | 0.72 | TP53 (0.53) | TP53SCDLMNAHDAC6TRPA1 | |
| SCHEMBL7081478 | 0.71 | TP53 (0.52) | TP53SCDLMNAHDAC6TRPA1 | |
| SCHEMBL3358550 | 0.71 | SCD (0.83) | TP53SCDHDAC6TRPA1 | |
| SCHEMBL5532025 | 0.70 | RAB9A (0.65) | SCDMEN1KMT2A | |
| SCHEMBL23535856 | 0.70 | MAPK1 (0.48) | TP53SCDLMNAHDAC6VEGFA | |
| SCHEMBL31715259 | 0.69 | SCD (0.48) | TP53SCDHDAC6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME LLC (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2021127071-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | ZC3HAV1, HDAC11, CXCR1 | TP53 499/4885SCD 4673/4885LMNA 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.